| Identification | Back Directory | [Name]
Diproteverine | [CAS]
69373-95-1 | [Synonyms]
BRL-40015
Diproteverine
1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline
1-[(3,4-Diethoxyphenyl)methyl]-3,4-dihydro-6,7-bis(1-methylethoxy)isoquinoline | [Molecular Formula]
C26H35NO4 | [MDL Number]
MFCD00864682 | [MOL File]
69373-95-1.mol | [Molecular Weight]
425.565 |
| Hazard Information | Back Directory | [Uses]
Diproteverine (BRL 40015) is an oral activity calcium channel blocker. Diproteverine embryonic toxicity. Diproteverine also shows antianginal properties[1][2]. | [in vivo]
Diproteverine (40, 80, 160, 320 mg/kg; p.o.; daily for 10 days) shows embryonic toxicity in rats[1]. | Animal Model: | Sprague-Dawley virgin female rats[1] | | Dosage: | 40, 80, 160, 320 mg/kg | | Administration: | P.o.; daily for 10 days | | Result: | Induced embryonic deaths, significantly increased incidence of fetuses showing an unusual pattern of digital, tail, heart, and vertebral abnormalities. |
| [References]
[1] Ridings JE, et al. Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9. DOI:10.1016/0890-6238(95)02017-9
[2] Lacroix P, et al. Diproteverine (BRL 40015): a new type of calcium antagonist with potential antianginal properties. Eur J Pharmacol. 1991 Jan 17;192(3):317-27. DOI:10.1016/0014-2999(91)90220-k |
|
|